The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.
 
Michiel Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 4SC (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (Inst)
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Catalym; Genenta Science; Gilead Sciences; Incyte; Johnson & Johnson/Janssen; Merck Serono; Merck Sharp & Dohme; Peerview; PeerVoice; Samsung Bioepis; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Gilead Sciences (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Janssen; Merck Sharp & Dohme
 
Dingwei Ye
No Relationships to Disclose
 
Peng Zhang
No Relationships to Disclose
 
Aristotelis Bamias
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Debiopharm Group; MSD; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ferring; Ipsen; MSD; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Pfizer (Inst); Roche (Inst)
 
Pablo Maroto-Rey
Consulting or Advisory Role - Astellas Pharma; Bayer; BMS; Ipsen; Janssen; Merck/Pfizer; MSD
Expert Testimony - Amgen
Travel, Accommodations, Expenses - Bayer; Ipsen; Merck/Pfizer
 
Michel Pavic
Honoraria - Astellas Pharma; EMD Serono; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Forus; Janssen; Merck; Novartis; Pfizer; Sanofi
 
Jens Bedke
Consulting or Advisory Role - Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Eisai; Ipsen; Janssen; Merck KGaA; MSD Oncology; Pfizer; Roche
Speakers' Bureau - Apogepha; Astellas Pharma; Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst); Merck KGaA (Inst)
 
Ja Hyeon Ku
No Relationships to Disclose
 
Mauricio Burotto
Consulting or Advisory Role - BMS; MSD Oncology; Roche/Genentech
Speakers' Bureau - AstraZeneca; BMS
Travel, Accommodations, Expenses - BMSi; BMSi
 
Gwenaelle Gravis
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); BMS (Inst); Curium Pharma (Inst); Janssen (Inst); Merck/Pfizer (Inst)
Speakers' Bureau - Advanced Accelerator Applications (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Ipsen (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst)
Research Funding - BMS (Inst)
Expert Testimony - BAYER (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Pfizer
 
Jan Oldenburg
Consulting or Advisory Role - Accord Healthcare; Astellas Pharma; AstraZeneca; Bayer; BMS Norway; Eisai; Janssen Oncology; Merck KGaA; MSD Oncology; Pfizer; Roche/Genentech
Speakers' Bureau - Astellas Pharma
 
Yoshihiko Tomita
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Janssen; Merck; MSD; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Eisai; MSD; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
Yüksel Ürün
Honoraria - Abdi Ibrahim; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Gilead Sciences; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abdi Ibrahim; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Gilead Sciences; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - Abdi Ibrahim; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Abdi Ibrahim; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Pfizer; Roche
 
Jeiry Filian
No Relationships to Disclose
 
Anlong Li
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Emmanouil Spanakis
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Guru Sonpavde
Employment - Exact Sciences (I); Myriad Genetics (I)
Honoraria - Grand Rounds in Urology; Ideology Health; Onviv; PeerView; PrecisCa; UpToDate
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Janssen; Kura Oncology; Loxo/Lilly; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial
Speakers' Bureau - Astellas Pharma; AVEO; Bayer; Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Janssen Oncology; Medscape; Merck; Natera; Pfizer; Research to Practice; Seagen
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Sumitomo Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb
Other Relationship - Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Merck; Mereo BioPharma; QED Therapeutics